Yes, medical devices typically require on-site evaluations as part of the NMPA (National Medical Products Administration) registration process in China, particularly for higher-risk devices. Here are some key points about the on-site evaluation process:
Risk Classification: The NMPA categorizes medical devices into three classes based on their risk level. Class I devices generally require less stringent regulatory controls, while Class II and III devices undergo more extensive evaluations, including on-site inspections.
Manufacturing Site Inspection: For Class II and III devices, the NMPA may conduct on-site evaluations of the manufacturing site. This includes assessing the production processes, quality management systems, and compliance with Good Manufacturing Practices (GMP).
Evaluation Scope: During the on-site evaluation, inspectors may examine documentation related to design, production, quality control, and post-market surveillance. They may also conduct physical inspections of the facilities and equipment used in the manufacturing process.
Approval Timeline: The duration of the on-site evaluation can vary depending on the complexity of the device and the efficiency of the manufacturer in providing the required documentation and access to the site.
Preparation: Manufacturers should be well-prepared for the on-site evaluation. This includes having all necessary documentation organized and ensuring that the manufacturing processes align with the relevant standards.
Post-Evaluation Actions: After the on-site evaluation, the NMPA will review the findings and may request additional information or corrective actions before granting registration approval.
Overall, the on-site evaluation is a crucial step in ensuring that medical devices meet the regulatory requirements and safety standards in China.
.png)
